It began typically enough: the Supreme Court denied cert in Athena, Chargepoint and Trading Technologies; Brexit finally happened; the Federal Circuit refused to rehear Arthrex; and the IP community was waiting for important rulings in copyright cases like Google v. Oracle and trademark cases like Booking.com. But then came COVID. Courts and offices shut down, the USPTO went almost 100% remote, and all conferences and events were cancelled into 2021. At the same time, pharmaceuticals, vaccines – and the IP around them – became the only thing on anyone’s mind.
Recent Posts
- Recentive Rehearing Petition Challenges CAFC’s Broad Section 101 Exclusion of Machine Learning Inventions
- Other Barks & Bites for Friday, June 20: Advocate General Tells CJEU to Affirm €4 Billion Antitrust Fine Against Google; Recentive Challenges Section 101 Invalidation of Machine Learning Claims
- Stewart Expands on ‘Settled Expectations’ Criteria in Interim Discretionary Denial Process
- Mediocre Results so Far for Deferred Subject Matter Eligibility Response Pilot
- European Patent Organization: Responses from ChatGPT Do Not Represent the “Understanding of a Skilled Person”